肺生検の世界市場の評価：製品タイプ・処置・エンドユーザー・地域別の機会および予測 (2017～2031年)

世界の肺生検の市場規模は、2024年から2031年の予測期間中にCAGR 11.27％を記録し、2023年の30億1,000万米ドルから、2031年には70億7,000万米ドルの規模に成長すると予測されています。

肺生検の市場は、肺癌やその他の呼吸器疾患の有病率の上昇、肺癌の早期発見・同定に対する需要の高まり、低侵襲手術の普及といった促進要因の影響を受けて成長すると予想されています。AQIレベルの悪化、タバコの消費の増加、空気中の発癌物質の存在が肺癌の有病率増加の主な要因です。肺の予備的な画像分析に続いて、癌細胞の確認のために生検と内視鏡検査が行われます。肺癌患者の増加に伴い、肺生検ソリューションの需要は大幅に増加すると予想されています。さらに、癌症例に関連する懸念に対処する政府の取り組みや、さまざまな機関が実施している啓発キャンペーンも生検を含む診断手順を大幅に促進しています。

肺生検におけるロボット技術の採用の増加

ロボット技術は、医療専門家が高精度で低侵襲な処置を行うのを支援します。生検デバイスの有効性を高めるためのAI、機械学習アルゴリズム、その他の類似技術の使用が市場の主要動向です。ロボット肺生検は、ロボット支援技術を用いて癌診断処置を行い、治療方針を導くのに役立ちます。

肺癌の有病率の増加

肺癌の有病率は、特にタバコの喫煙や工業化が進む途上国で増加しています。肺癌は世界の癌罹患率および死亡率の第一位です。現在の状況における肺癌の主な原因としては、大気汚染の増加と、空気中の発癌物質やPM2.5粒子の存在が挙げられます。先進諸国では肺癌患者の大幅な減少が観察されていますが、新興諸国では依然として憂慮すべき状態にあります。禁煙へのシフトとCO2排出量削減の取り組みは、長期的には肺癌患者の減少に有望と思われます。肺癌の有病率の増加は、早期診断と効果的な治療方法を確実にするための肺生検ソリューションに対する需要を高めています。WHOによると、肺癌は世界で最もよく発生する癌と考えられており、新規症例は250万例で新規症例全体の12.4％を占めています。肺癌は、癌による死亡者数の18.7%に当たる約180万人を占め、癌による死亡の主な原因です。

針生検は処置の面で世界の肺生検市場を独占する

針生検は、その非侵襲性、スピード、利便性、安全性により、肺癌診断において大きな人気を得ています。開腹肺生検と比較すると、細針吸引 (FNA) やコアニードル生検 (CNB) のような針生検は侵襲性が低く、迅速で、患者はその日のうちに帰宅できる場合が多いです。これらの処置は正確な診断を提供し、費用対効果も高いため、患者や医療システムにとってより利用しやすいものとなっています。しかし、針生検はごく少量の組織を採取するため限界があり、特定の検査や診断には十分でない場合があります。

当レポートでは、世界の肺生検の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の肺生検市場の展望

• 市場規模・予測
• 製品タイプ別
  • コアニードル生検デバイス
  • 細針吸引生検デバイス
  • 外科用生検デバイス
  • 真空支援生検デバイス
• 処置別
  • 針生検
  • 胸腔鏡生検
  • 経気管支生検
  • オープンバイオプシー
• エンドユーザー別
  • 病院
  • 癌研究センター
  • 専門クリニック
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界の肺生検市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 製品タイプ別
• 処置別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需要供給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Becton, Dickinson and Company
• Boston Scientific Corporation
• Medtronic plc
• Intuitive Surgical, Inc.
• Argon Medical Devices, Inc.
• Olympus Corporation
• Hologic, Inc.
• DTR Medical Ltd
• B. Braun Melsungen AG
• Ethicon, Inc. (Johnson & Johnson)

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 2. Global Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 3. Global Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 4. Global Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 5. Global Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 6. Global Lung Biopsy Market Share (%), By Region, 2017-2031F
• Figure 7. North America Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 8. North America Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 9. North America Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 10. North America Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 11. North America Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 12. North America Lung Biopsy Market Share (%), By Country, 2017-2031F
• Figure 13. United States Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 14. United States Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 15. United States Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 16. United States Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 17. United States Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 18. Canada Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 19. Canada Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 20. Canada Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 21. Canada Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 22. Canada Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 23. Mexico Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 24. Mexico Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 25. Mexico Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 26. Mexico Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 27. Mexico Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 28. Europe Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 29. Europe Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 30. Europe Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 31. Europe Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 32. Europe Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 33. Europe Lung Biopsy Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 35. Germany Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 36. Germany Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 37. Germany Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 38. Germany Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 39. France Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 40. France Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 41. France Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 42. France Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 43. France Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 44. Italy Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 45. Italy Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 46. Italy Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 47. Italy Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 48. Italy Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 49. United Kingdom Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 50. United Kingdom Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 51. United Kingdom Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 52. United Kingdom Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 53. United Kingdom Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 54. Russia Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 55. Russia Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 56. Russia Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 57. Russia Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 58. Russia Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 59. Netherlands Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 60. Netherlands Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 61. Netherlands Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 62. Netherlands Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 63. Netherlands Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 64. Spain Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 65. Spain Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 66. Spain Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 67. Spain Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 68. Spain Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 69. Turkey Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 70. Turkey Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 71. Turkey Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 72. Turkey Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 73. Turkey Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 74. Poland Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 75. Poland Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 76. Poland Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 77. Poland Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 78. Poland Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 79. South America Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 80. South America Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 81. South America Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 82. South America Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 83. South America Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 84. South America Lung Biopsy Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 86. Brazil Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 87. Brazil Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 88. Brazil Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 89. Brazil Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 90. Argentina Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 91. Argentina Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 92. Argentina Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 93. Argentina Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 94. Argentina Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 95. Asia-Pacific Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 97. Asia-Pacific Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 98. Asia-Pacific Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 99. Asia-Pacific Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 100. Asia-Pacific Lung Biopsy Market Share (%), By Country, 2017-2031F
• Figure 101. India Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 102. India Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 103. India Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 104. India Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 105. India Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 106. China Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 107. China Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 108. China Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 109. China Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 110. China Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 111. Japan Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 112. Japan Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 113. Japan Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 114. Japan Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 115. Japan Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 116. Australia Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 117. Australia Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 118. Australia Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 119. Australia Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 120. Australia Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 121. Vietnam Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 122. Vietnam Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 123. Vietnam Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 124. Vietnam Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 125. Vietnam Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 126. South Korea Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 127. South Korea Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 128. South Korea Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 129. South Korea Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 130. South Korea Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 131. Indonesia Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 132. Indonesia Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 133. Indonesia Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 134. Indonesia Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 135. Indonesia Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 136. Philippines Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 137. Philippines Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 138. Philippines Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 139. Philippines Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 140. Philippines Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 141. Middle East & Africa Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 143. Middle East & Africa Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 144. Middle East & Africa Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 145. Middle East & Africa Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 146. Middle East & Africa Lung Biopsy Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 149. Saudi Arabia Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 150. Saudi Arabia Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 151. Saudi Arabia Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 152. UAE Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 153. UAE Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 154. UAE Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 155. UAE Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 156. UAE Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 157. South Africa Lung Biopsy Market, By Value, in USD Billion, 2017-2031F
• Figure 158. South Africa Lung Biopsy Market, By Volume, in Million Units, 2017-2031F
• Figure 159. South Africa Lung Biopsy Market Share (%), By Product Type, 2017-2031F
• Figure 160. South Africa Lung Biopsy Market Share (%), By Procedure Type, 2017-2031F
• Figure 161. South Africa Lung Biopsy Market Share (%), By End-user, 2017-2031F
• Figure 162. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Procedure Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global lung biopsy market is projected to witness a CAGR of 11.27% during the forecast period 2024-2031, growing from USD 3.01 billion in 2023 to USD 7.07 billion in 2031F. The lung biopsy market is expected to thrive under the impact of drivers such as the rising prevalence of lung cancer and other respiratory diseases, the growing demand for early identification and detection of lung cancer, and the increasing popularity of minimally invasive surgeries. Deteriorating AQI levels, increasing consumption of tobacco, and the presence of carcinogens in the air are major factors contributing to the increasing prevalence of lung cancer. Followed by the preliminary imaging analysis of the lungs, the biopsy and endoscopy procedures are performed for confirmation of cancer cells. With rising cases of lung cancer, the demand for lung biopsy solutions is anticipated to increase significantly. Additionally, the government initiatives addressing the concerns associated with cancer cases and awareness campaigns being run by various authorities significantly promoted the diagnosis procedures including biopsies.

However, the high cost of biopsy procedures and equipment associated with lung cancer is a major challenge for market expansion in middle and low-income regions. The availability of alternate diagnostic methods like imaging analysis, rapid testing facilities, and others poses a significant pushback to the adoption of biopsy methods. Alongside, stringent regulatory guidelines for the manufacturing of biopsy instruments and carrying out biopsy procedures are major challenges for key players to expand the market growth. Despite these challenges, the market is witnessing promising growth.

For instance, in October 2023, Delfi Diagnostics launched a new product called FirstLook Lung. The product aims to identify individuals who could benefit the most from lung cancer screening. It uses a novel approach to liquid biopsy, which involves the detection of DNA fragments in the blood to identify the tumors. Delfi focuses primarily on lung cancer, which is the leading cause of cancer-related deaths.

Increasing Adoption of Robotics in Lung Biopsy

Robotic technology aids healthcare professionals to perform minimally invasive procedures with high accuracy. The use of artificial intelligence, machine learning algorithms, and other similar technologies to enhance the efficacy of biopsy devices is a major key trend in the market. Robotic lung biopsies use robotic-assisted technology to perform cancer diagnostic procedures and help guide the course of treatment.

With the rising demand for minimally invasive procedures, lung biopsies are being performed through robots along with the integration of artificial intelligence and other tools for better clinical outcomes. It increases the speed and accuracy of diagnosis, further contributing to the advancements in the market.

In March 2023, Noah Medical announced its clinical trial at Macquarie University Hospital in Sydney, Australia. The trial, called FRONTIER, is the first-in-human study that aims to evaluate the safety and feasibility of the Galaxy System. The system is designed to enhance the accuracy of locating and diagnosing lung nodules using its TiLT+ technology. The Galaxy System features integrated tomosynthesis and augmented fluoroscopy in its TiLT+ technology, a single-use disposable bronchoscope, and a small, compact design that improves procedural workflow.

Increasing Prevalence of Lung Cancer

The prevalence of lung cancer is growing, particularly in developing nations where tobacco smoking and industrialization are increasing. Lung cancer is the leading cause of global cancer incidence and mortality. Major reasons for lung cancer in the present scenario include increasing air pollution and the presence of carcinogens and PM 2.5 particles in the air. A significant decrease in lung cancer cases has been observed in developed nations but the condition is still at an alarming rate in states belonging to emerging countries. The shift towards smoking cessation and initiatives for reducing CO2 emissions seem promising in reducing lung cancer cases in the long run. The increasing prevalence of lung cancer is increasing the demand for lung biopsy solutions to ensure early diagnosis and effective treatment methodologies. As per WHO, lung cancer is considered the most commonly occurring cancer worldwide with 2.5 million new cases accounting for 12.4% of the total new cases. Lung cancer is the leading cause of cancer deaths accounting for about 1.8 million deaths, which is 18.7% of the total cancer deaths.

Needle Biopsy Dominates Global Lung Biopsy Market in Terms of Procedure

Needle biopsies have gained significant popularity in lung cancer diagnosis due to their non-invasive nature, speed, convenience, and safety. Compared to open lung biopsy, needle biopsies like fine needle aspiration (FNA) and core needle biopsy (CNB) are less invasive, quicker, and often allow patients to return home the same day. These procedures provide accurate diagnoses and are cost-effective, making them more accessible for patients and healthcare systems. However, needle biopsies have limitations, as they remove a very small amount of tissue, which may not be sufficient for certain tests or diagnosis.

For instance, in November 2023, Broncus Medical Inc. announced the launch of BioStar Transbronchial Aspiration Needle (TBNA) which aims to transform the landscape of minimally invasive diagnostics. The innovative needle sets a new standard in accuracy, ease of use, and patient comfort. It offers medical professionals an unprecedented tool for precise tissue sampling, providing high-quality specimens needed for establishing a reliable tool for diagnosing the stage of lung cancer. The needle is available in 21G, 22G, and 25G configurations.

Hospitals to be the Dominant End-user of Lung Biopsy

Hospitals are the major end-users of lung biopsy products as they provide round-the-clock services to patients and are equipped with advanced medical equipment. Medical professionals who have expertise in lung biopsy systems are easily available in the hospital premises. Besides, hospitals offer patients better access to healthcare services which can result in a huge number of lung biopsies being performed. Hospitals are expanding their service offerings through the adoption of robotics and other technologies. In August 2023, the first robotic-assisted lung biopsy was performed at Royal Brompton Hospital and St Bartholomew's Hospital, the United Kingdom to aid in early diagnosis. The robotic-assisted lung biopsy surgery was performed by the Ion Endoluminal robotic system.

North America is the Leading Region with Highest Market Share

North America is anticipated to be the leading region in the lung biopsy market. Many lung cancer biopsies in North America are performed due to several factors, including the high prevalence of lung cancer, the need for accurate diagnosis, and lack of effective routine screening methods. Lung cancer is the leading cause of cancer-related deaths in the United States, and its rapid growth and tendency to spread make early detection and diagnosis critical for successful treatment. Additionally, the availability of specialized techniques and the presence of a large number of healthcare providers and facilities in the United States contribute to the high frequency of biopsies. Furthermore, grants for developing innovative biopsy solutions strengthen the dominance of North America.

For instance, in October 2023, radiology experts from The University of California, Los Angeles scored a USD 4.6 million grant from the National Institutes of Health for the development of liquid biopsy technology for the early detection of lung cancer. Liquid biopsy is a non-invasive alternative, allowing physicians to determine the molecular composition of a tumor without extracting tissue or performing any surgery.

Future Market Scenario (2024 - 2031F)

Liquid biopsy has seen significant advancements in the diagnosis and management of lung cancer. It is a minimally invasive approach that involves the detection of molecular alterations, tumor cells, and metabolites in body fluids such as blood, urine, sputum, and saliva. In recent times, several market products have been initiated to cater to the demand for liquid biopsy for lung cancer. Additionally, products based on virtual biopsy and image-guided biopsy methods are in the pipeline promising growth for the market.

For instance, in May 2023, Guardant Health, Inc. shared that Singapore's Health Sciences Authority (HSA) has given regulatory approval to Guardant360 CDx. It is a liquid biopsy test that detects tumor mutation profiling, known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardant360 CDx test has been approved as a companion diagnostic tool for identifying patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with TAGRISSO (osimertinib).

Key Players Landscape and Outlook

Key players in lung biopsy market include key players from various levels including big players as well as emerging startups. Industry collaboration between medical device manufacturers and technology providers is crucial for the integration of technologies in biopsy devices. Significant mergers and acquisitions have been witnessed in recent times as well. Grants from several authorities for developing suitable solutions will further expand the market.

In February 2024, Renovaro Biosciences announced that its newly acquired subsidiary, GediCube, secured a binding letter of intent (LOI) for the acquisition of 75% of Dutch liquid biopsy firm Cyclomics, which developed a circulating tumor DNA detection technology using Oxford Nanopore sequencing. Cyclomics aims to use the technique for the development of multi-omic tests that can be run using a single vial of blood for early detection of cancer, recurrence monitoring, and precision oncology treatment.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Lung Biopsy Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Product Type
  • 4.2.1. Core Needle Biopsy Devices
  • 4.2.2. Fine Needle Aspiration Biopsy Devices
  • 4.2.3. Surgical Biopsy Devices
  • 4.2.4. Vacuum-Assisted Biopsy Devices
• 4.3. By Procedure Type
  • 4.3.1. Needle Biopsy
  • 4.3.2. Thoracoscopic Biopsy
  • 4.3.3. Transbronchial Biopsy
  • 4.3.4. Open Biopsy
• 4.4. By End-user
  • 4.4.1. Hospitals
  • 4.4.2. Cancer Research Centers
  • 4.4.3. Specialty Clinics
  • 4.4.4. Others
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia-Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East and Africa
• 4.6. By Company Market Share (%), 2023

5. Global Lung Biopsy Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Product Type
    • 5.1.2.1. Core Needle Biopsy Devices
    • 5.1.2.2. Fine Needle Aspiration Biopsy Devices
    • 5.1.2.3. Surgical Biopsy Devices
    • 5.1.2.4. Vacuum-Assisted Biopsy Devices
  • 5.1.3. By Procedure Type
    • 5.1.3.1. Needle Biopsy
    • 5.1.3.2. Thoracoscopic Biopsy
    • 5.1.3.3. Transbronchial Biopsy
    • 5.1.3.4. Open Biopsy
  • 5.1.4. By End-user
    • 5.1.4.1. Hospitals
    • 5.1.4.2. Cancer Research Centers
    • 5.1.4.3. Specialty Clinics
    • 5.1.4.4. Others
  • 5.1.5. United States*
    • 5.1.5.1. Market Size & Forecast
    • 5.1.5.1.1. By Value
    • 5.1.5.1.2. By Volume
    • 5.1.5.2. By Product Type
    • 5.1.5.2.1. Core Needle Biopsy Devices
    • 5.1.5.2.2. Fine Needle Aspiration Biopsy Devices
    • 5.1.5.2.3. Surgical Biopsy Devices
    • 5.1.5.2.4. Vacuum-Assisted Biopsy Devices
    • 5.1.5.3. By Procedure Type
    • 5.1.5.3.1. Needle Biopsy
    • 5.1.5.3.2. Thoracoscopic Biopsy
    • 5.1.5.3.3. Transbronchial Biopsy
    • 5.1.5.3.4. Open Biopsy
    • 5.1.5.4. By End-user
    • 5.1.5.4.1. Hospitals
    • 5.1.5.4.2. Cancer Research Centers
    • 5.1.5.4.3. Specialty Clinics
    • 5.1.5.4.4. Others
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Product Type
• 6.2. By Procedure Type
• 6.3. By End-user
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Demand Supply Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.4.7. Supplier Power
  • 7.4.8. Buyer Power
  • 7.4.9. Substitution Threat
  • 7.4.10. Threat from New Entrant
  • 7.4.11. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Becton, Dickinson and Company
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Boston Scientific Corporation
• 13.3. Medtronic plc
• 13.4. Intuitive Surgical, Inc.
• 13.5. Argon Medical Devices, Inc.
• 13.6. Olympus Corporation
• 13.7. Hologic, Inc.
• 13.8. DTR Medical Ltd
• 13.9. B. Braun Melsungen AG
• 13.10. Ethicon, Inc. (Johnson & Johnson)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer